Sino Biological has developed a large panel of reagents for COVID19 research. The most important application of these reagents is in serological diagnostics, both in forms of antigen detection and antibody detection. Sino Biological's recombinant S protein and N protein have both been used to manufacture diagnostic kits detecting serum antibodies against SARS-CoV-2.
The antigen detection is more difficult as compared to antibody detection, as the viral titer in sera and nasal swabs is often low. Sino Biological has released the world-first ELISA kits for the detection of SARS-CoV-2 N and S proteins. Several monoclonal antibodies developed by Sino Biological have been used in clinical testing of antigen detection, and received promising early results.
Earlier this year, Sino Biological has received support from the Bill & Melinda Gates Foundation on colloidal gold and ELISA based diagnosis of COVID-19. The fund will be specifically used for the optimization of key antigen and antibodies needed for rapid and high throughput detection of SARS-CoV-2.
These kits employ a standard sandwich ELISA format, allowing rapid quantification of the N and S antigens. All antibodies used in the kits are in-house developed monoclonal antibodies, ensuring batch-to-batch consistency. These assays may be used to quantify antigens on the surface of SARS-CoV-2 and/or pseudovirus (S Kit), as well as antigens expressed recombinantly (S Kit & N Kit).
This Kit makes available a rapid and high-throughput screening of neutralization antibodies and other blocking agents for SARS-CoV-2.